Development and preliminary verification of the evaluation system for clinical practice guidelines in China

Objective: Clinical practice guidelines can improve healthcare processes and patient outcomes; however, the quality of these guidelines varies greatly in China. The aim of this study was to construct a comprehensive instrument for the appraisal of clinical practice guidelines in China (AGREE-CHINA),...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ji-Yao Wang, Qiang Wang, Xiao-Qin Wang, Xue-Juan Jin, Bo-Heng Zhang, Shi-Yao Chen, Xue-Cheng Gao
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2020
Materias:	Appraisal of guidelines research and evaluation China Development Verification Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/6f939033c21d482fa03614adbbceddf9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6f939033c21d482fa03614adbbceddf9
record_format	dspace
spelling	oai:doaj.org-article:6f939033c21d482fa03614adbbceddf92021-12-02T14:17:18ZDevelopment and preliminary verification of the evaluation system for clinical practice guidelines in China2095-882X10.1016/j.cdtm.2019.08.007https://doaj.org/article/6f939033c21d482fa03614adbbceddf92020-06-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X19300726https://doaj.org/toc/2095-882XObjective: Clinical practice guidelines can improve healthcare processes and patient outcomes; however, the quality of these guidelines varies greatly in China. The aim of this study was to construct a comprehensive instrument for the appraisal of clinical practice guidelines in China (AGREE-CHINA), and to validate its reliability as a tool for helping potential guideline users in assessing guideline quality. Methods: First, an interdisciplinary working group was established for developing the methods. They also created a checklist as a tool according to the Appraisal of Guidelines, Research and Evaluation II (AGREE II) standards, considering the particularity of Chinese clinical practice. Next, the first draft of AGREE-China was developed by vote, modification, preliminary trial, and cross-verification. To ensure the objectivity, credibility, and reproducibility of the draft assessment, all of the checklists and standards were cross-reviewed fairly widely. Finally, AGREE-CHINA and AGREE II were used to assess the Chinese guidelines published in the past five years, and the results were compared. Results: The presented AGREE-CHINA covered five main checkpoints (science and rigor, effectiveness and safety, economy, usability and feasibility, and conflicts of interest) with each point divided into several more specific checkpoints. Definitions and rationales for each main checkpoint appear in the Appendix. The quality ratings based on the total scores of AGREE-China and AGREE II were consistent (r = 0.508, P = 0.020). Compared with AGREE II, the study showed a higher level of interrater-reliability for AGREE-CHINA overall (ICC = 0.957, P < 0.001). The mean time required for AGREE-CHINA was less than that for AGREE II; this was approximately 30 minutes for every assessment. User satisfaction was generally high. Conclusions: This paper has presented the first edition of the AGREE-CHINA appraisal tool for clinical guidelines. It is quick and easy to use; it assesses and performs well in comparison to AGREE II. This first version of AGREE-CHINA will require further development and validation.Ji-Yao WangQiang WangXiao-Qin WangXue-Juan JinBo-Heng ZhangShi-Yao ChenXue-Cheng GaoKeAi Communications Co., Ltd.articleAppraisal of guidelines research and evaluationChinaDevelopmentVerificationMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 6, Iss 2, Pp 134-139 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Appraisal of guidelines research and evaluation China Development Verification Medicine (General) R5-920
spellingShingle	Appraisal of guidelines research and evaluation China Development Verification Medicine (General) R5-920 Ji-Yao Wang Qiang Wang Xiao-Qin Wang Xue-Juan Jin Bo-Heng Zhang Shi-Yao Chen Xue-Cheng Gao Development and preliminary verification of the evaluation system for clinical practice guidelines in China
description	Objective: Clinical practice guidelines can improve healthcare processes and patient outcomes; however, the quality of these guidelines varies greatly in China. The aim of this study was to construct a comprehensive instrument for the appraisal of clinical practice guidelines in China (AGREE-CHINA), and to validate its reliability as a tool for helping potential guideline users in assessing guideline quality. Methods: First, an interdisciplinary working group was established for developing the methods. They also created a checklist as a tool according to the Appraisal of Guidelines, Research and Evaluation II (AGREE II) standards, considering the particularity of Chinese clinical practice. Next, the first draft of AGREE-China was developed by vote, modification, preliminary trial, and cross-verification. To ensure the objectivity, credibility, and reproducibility of the draft assessment, all of the checklists and standards were cross-reviewed fairly widely. Finally, AGREE-CHINA and AGREE II were used to assess the Chinese guidelines published in the past five years, and the results were compared. Results: The presented AGREE-CHINA covered five main checkpoints (science and rigor, effectiveness and safety, economy, usability and feasibility, and conflicts of interest) with each point divided into several more specific checkpoints. Definitions and rationales for each main checkpoint appear in the Appendix. The quality ratings based on the total scores of AGREE-China and AGREE II were consistent (r = 0.508, P = 0.020). Compared with AGREE II, the study showed a higher level of interrater-reliability for AGREE-CHINA overall (ICC = 0.957, P < 0.001). The mean time required for AGREE-CHINA was less than that for AGREE II; this was approximately 30 minutes for every assessment. User satisfaction was generally high. Conclusions: This paper has presented the first edition of the AGREE-CHINA appraisal tool for clinical guidelines. It is quick and easy to use; it assesses and performs well in comparison to AGREE II. This first version of AGREE-CHINA will require further development and validation.
format	article
author	Ji-Yao Wang Qiang Wang Xiao-Qin Wang Xue-Juan Jin Bo-Heng Zhang Shi-Yao Chen Xue-Cheng Gao
author_facet	Ji-Yao Wang Qiang Wang Xiao-Qin Wang Xue-Juan Jin Bo-Heng Zhang Shi-Yao Chen Xue-Cheng Gao
author_sort	Ji-Yao Wang
title	Development and preliminary verification of the evaluation system for clinical practice guidelines in China
title_short	Development and preliminary verification of the evaluation system for clinical practice guidelines in China
title_full	Development and preliminary verification of the evaluation system for clinical practice guidelines in China
title_fullStr	Development and preliminary verification of the evaluation system for clinical practice guidelines in China
title_full_unstemmed	Development and preliminary verification of the evaluation system for clinical practice guidelines in China
title_sort	development and preliminary verification of the evaluation system for clinical practice guidelines in china
publisher	KeAi Communications Co., Ltd.
publishDate	2020
url	https://doaj.org/article/6f939033c21d482fa03614adbbceddf9
work_keys_str_mv	AT jiyaowang developmentandpreliminaryverificationoftheevaluationsystemforclinicalpracticeguidelinesinchina AT qiangwang developmentandpreliminaryverificationoftheevaluationsystemforclinicalpracticeguidelinesinchina AT xiaoqinwang developmentandpreliminaryverificationoftheevaluationsystemforclinicalpracticeguidelinesinchina AT xuejuanjin developmentandpreliminaryverificationoftheevaluationsystemforclinicalpracticeguidelinesinchina AT bohengzhang developmentandpreliminaryverificationoftheevaluationsystemforclinicalpracticeguidelinesinchina AT shiyaochen developmentandpreliminaryverificationoftheevaluationsystemforclinicalpracticeguidelinesinchina AT xuechenggao developmentandpreliminaryverificationoftheevaluationsystemforclinicalpracticeguidelinesinchina
_version_	1718391611471167488

Development and preliminary verification of the evaluation system for clinical practice guidelines in China

Ejemplares similares